Results 1 to 10 of about 18,679,675 (294)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK) [PDF]

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Phosphoinositide 3-kinases (PI3K) and phosphoinositide 3-kinase-related protein kinases (PIKK) are two structurally related families of kinases that play vital roles in cell growth and DNA damage repair.
Xueqin Huang, Li You, Eugenie Nepovimova, Miroslav Psotka, David Malinak, Marian Valko, Ladislav Sivak, Jan Korabecny, Zbynek Heger, Vojtech Adam, Qinghua Wu, Kamil Kuca   +11 more
doaj   +3 more sources

A specific role for phosphoinositide 3-kinase and AKT in osteoblasts?

Frontiers in Endocrinology, 2012
The phosphoinositide 3-kinase and AKT (Protein Kinase B, PKB) signalling pathway (PI3K/AKT) plays a central role in the control of cell survival, growth and proliferation throughout the body.
Imelda Mary McGonnell, Agamemnon Emil Grigoriadis, Eric W-F. Lam, Joanne S Price, Andrew eSunters   +4 more
doaj   +3 more sources

The Importance of Phosphoinositide 3-Kinase in Neuroinflammation. [PDF]

Int J Mol Sci
Neuroinflammation, characterised by the activation of immune cells in the central nervous system (CNS), plays a dual role in both protecting against and contributing to the progression of neurodegenerative diseases, such as Alzheimer’s disease (AD) and multiple sclerosis (MS).
Wright B, King S, Suphioglu C.
europepmc   +3 more sources

Phosphoinositide 3-kinase δ activity in patients with systemic lupus erythematosus [PDF]

Frontiers in Immunology
IntroductionNew biomarkers are needed for better stratification and personalized treatment of Systemic Lupus Erythematosus (SLE). Phosphoinositide 3-kinase δ (PI3Kδ) has been implicated in SLE pathogenesis.
Elham Sadat Mirfazeli, Elham Sadat Mirfazeli, Shalmalee Kharkar, Shalmalee Kharkar, Michel W. P. Tsang-A-Sjoe, Olivier Papapietro, Olivier Papapietro, Olivier Papapietro, Izabella Niewczas, Agner R. Parra Sanchez, Agner R. Parra Sanchez, Anita Chandra, Anita Chandra, Klaus Okkenhaug, Irene E. M. Bultink, Irene E. M. Bultink, Reina E. Mebius, Reina E. Mebius, Jonathan Clark, Alexandre E. Voskuyl, Alexandre E. Voskuyl, Sergey Nejentsev, Sergey Nejentsev, Sergey Nejentsev   +23 more
doaj   +2 more sources

Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment [PDF]

Pediatric Discovery
Activated phosphoinositide 3‐kinase delta syndrome (APDS) is an autosomal dominant inborn errors of immunity resulting from gain of function mutations in the PIK3CD gene or loss of function mutations in the PIK3R1 gene.
Ke Zhu, Qifan Li, Lingli Han, Jinqiao Sun   +3 more
doaj   +2 more sources

A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer [PDF]

Nature Communications
The deregulated activation of the phosphoinositide 3-kinase (PI3K) pathway is a hallmark of aggressive tumors with metabolic plasticity, eliciting their adaptation to the microenvironment and resistance to chemotherapy. A significant gap lies between the
Guillaume P. Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, Etienne Lengliné, Ambroise Marçais, Alexandre Théron, Grégoire Huré, Jérome Doss, Ivan Nemazanyy, Marie Émilie Dourthe, Nicolas Boissel, Hervé Dombret, Philippe Rousselot, Olivier Hermine, Vahid Asnafi   +14 more
doaj   +2 more sources

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

Frontiers in Immunology, 2018
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency.
Maria Elena Maccari, Maria Elena Maccari, Hassan Abolhassani, Hassan Abolhassani, Asghar Aghamohammadi, Alessandro Aiuti, Olga Aleinikova, Catherine Bangs, Safa Baris, Federica Barzaghi, Helen Baxendale, Matthew Buckland, Siobhan O. Burns, Caterina Cancrini, Caterina Cancrini, Andrew Cant, Pascal Cathébras, Marina Cavazzana, Marina Cavazzana, Marina Cavazzana, Anita Chandra, Anita Chandra, Francesca Conti, Francesca Conti, Tanya Coulter, Lisa A. Devlin, J. David M. Edgar, Saul Faust, Alain Fischer, Alain Fischer, Alain Fischer, Marina Garcia Prat, Lennart Hammarström, Maximilian Heeg, Maximilian Heeg, Stephen Jolles, Elif Karakoc-Aydiner, Gerhard Kindle, Ayca Kiykim, Dinakantha Kumararatne, Bodo Grimbacher, Hilary Longhurst, Nizar Mahlaoui, Nizar Mahlaoui, Tomas Milota, Fernando Moreira, Despina Moshous, Despina Moshous, Despina Moshous, Anna Mukhina, Olaf Neth, Benedicte Neven, Benedicte Neven, Benedicte Neven, Alexandra Nieters, Peter Olbrich, Ahmet Ozen, Jana Pachlopnik Schmid, Capucine Picard, Capucine Picard, Seraina Prader, William Rae, Janine Reichenbach, Stephan Rusch, Sinisa Savic, Alessia Scarselli, Alessia Scarselli, Raphael Scheible, Anna Sediva, Svetlana O. Sharapova, Anna Shcherbina, Mary Slatter, Pere Soler-Palacin, Aurelie Stanislas, Felipe Suarez, Francesca Tucci, Annette Uhlmann, Joris van Montfrans, Klaus Warnatz, Anthony Peter Williams, Phil Wood, Sven Kracker, Sven Kracker, Alison Mary Condliffe, Stephan Ehl, Stephan Ehl   +85 more
doaj   +3 more sources

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome [PDF]

Frontiers in Pharmacology
Graphical AbstractIC50 = 11 nM (PI3Kδ); 244 nM (PI3Kα); 424 nM (PI3Kβ), 2,230 nM (PI3Kγ).
Surya K. De, Surya K. De
doaj   +2 more sources

Inhibiting phosphoinositide 3-kinases [PDF]

Cancer Biology & Therapy, 2005
Commentary to:PWT-458, A Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid TumorsK. Yu, J. Lucas, T. Zhu, A. Zask, C. Gaydos, L. Toral-Barza, J. Gu, F. Li, I. Chaudhary, P. Cai, J. Lotvin, R. Petersen, M. Ruppen, M. Fawzi, S. Ayral-Kaloustian, J. Skotnicki, T. Mansour, P.
Yardena, Samuels, Jiuxiang, Zhu, Christoph, Lengauer   +2 more
openaire   +2 more sources

Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer’s Disease

Cells, 2022
Alzheimer’s disease (AD) is a common age-related neurodegenerative disease that leads to memory loss and cognitive function damage due to intracerebral neurofibrillary tangles (NFTs) and amyloid-β (Aβ) protein deposition.
Shaobin Yang, Yaqin Du, Xiaoqian Zhao, Chendong Wu, Peng Yu   +4 more
doaj   +1 more source